Zdrowie i gospodarka · 22/12/1999
Draft Guidance for Industry on Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by the Center for Drug Evaluation and Research, Beginning on January 1, 2000; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by the Center for Drug Evaluation and Research, Beginning on January 1, 2000.'' This document is intended to provide guidance to sponsors of applications that are the subject of an open advisory committee meeting convened by the Center for Drug Evaluation and Research (CDER), beginning January 1, 2000. The draft guidance describes procedures that will be adopted by CDER for making information provided to advisory committee members in connection with such meetings publicly available. The draft guidance also describes how a sponsor should prepare its submission to an advisory committee.